Sosei Heptares Partner Pfizer Report the First Patient Dosing of PF-07081532 in the P-II Clinical Trial for the Treatment of Type 2 Diabetes and Obesity
Shots:
- Sosei Heptares' Partner Pfizer highlighted the dosing of the first patient in a P-II trial evaluating the safety & efficacy of PF-07081532 vs PBO in 780 patients with Type 2 Diabetes Mellitus inadequately controlled on metformin, and in adults with obesity but without T2DM
- PF-07081532 is an oral small-molecule GLP-1 receptor agonist & is currently in development for T2D & obesity. The 2 other products are currently in the P-I trial i.e., PF-07054894 & PF-07258669
- Sosei Heptares will receive $10M upon achievement of milestones. In Nov 2015, Sosei Heptares collaborated with Pfizer to research & develop new therapies directed at GPCR targets across multiple therapeutic areas
Ref: Globenewswire | Image: Sosei Heptares
Related News:- Pfizer Initiates Clinical Study of Eighth Candidate Emerges Under the Collaboration with Sosei Heptares
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
